Systemic Sclerosis
305
57
67
143
Key Insights
Highlights
Success Rate
88% trial completion (above average)
Published Results
37 trials with published results (12%)
Research Maturity
143 completed trials (47% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
6.2%
19 terminated out of 305 trials
88.3%
+1.8% vs benchmark
9%
26 trials in Phase 3/4
26%
37 of 143 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 143 completed trials
Clinical Trials (305)
Assessment of Nutritional Status in Systemic Sclerosis
A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
Color Doppler Ultrasonography Evaluation of Abdominal and Peripheral Vasculopathy in Systemic Sclerosis Patients
Efficacy of a Personalized Rehabilitation Program of Facial Involvement in Systemic Sclerosis
EACVI Study on Multimodality Cardiovascular Imaging of Inflammatory Cardiovascular Diseases
A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
Bosentan in Systemic Sclerosis
A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)
A Study of AZD0120 in Autoimmune Diseases
Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)
A Phase 1 Open-label Study to Evaluate Safety in Healthy Participants and Participants With Autoimmune Diseases
Systemic Sclerosis and Innate T Cells
CD19/BCMA-Targeted Universal CAR-T Cell Injection for the Treatment of Autoimmune Diseases
A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis
Vasculopathy, Inflammation and Systemic Sclerosis
RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
Personalized Home Respiratory Rehabilitation Program for Subjects With Systemic Sclerosis With Early Lung Disease
Deployment o the Multidisciplinary Prospective Cohort Imminent
Evaluation of Aesthetic Impact in Patients With Systemic Sclerosis
Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases